More Shareholders Sue Medtronic, Inc. Over Infuse Claims

Another lawsuit is lodged against Medtronic accusing its officers and directors of falsely inflating its stock value through off-label promotion of its Infuse bone growth protein. Medtronic (NYSE:MDT) found itself at the center of another shareholder lawsuit accusing it of artificially boosting its stock price and forcing the company to repurchase more than $2.8 billion of its own shares at inflated rates. In a lawsuit filed this week, a clutch of investors accuse Medtronic's top brass of making misleading statements in filings with the SEC, calls with analysts, press releases and other public statements to conceal that it was actively promoting off-label use of its Infuse bone growth protein, which was in turn causing problems for patients, according to court documents.